EXPERIMENTAL DERMATOLOGY, published by WILEY, is a leading journal in the fields of Biochemistry and Dermatology, with impressive rankings including Q1 status in both categories as of 2023. With its ISSN 0906-6705 and E-ISSN 1600-0625, the journal offers a reputable platform for disseminating cutting-edge research and insights into skin biology and related health issues. As a pivotal resource for professionals, researchers, and students alike, EXPERIMENTAL DERMATOLOGY includes a broad scope of topics, fostering a deeper understanding of dermatological conditions and enhancing new therapeutic strategies. The journal’s distinguished performance is highlighted by its Scopus rankings, which place it at the 91st percentile in Medicine-Dermatology and the 65th in Biochemistry. While not an open-access publication, the journal remains committed to ensuring the accessibility of crucial developments within the dermatological community worldwide, facilitating the advancement of both clinical practice and academic inquiry.

SKIN RESEARCH AND TECHNOLOGY, a distinguished publication by Wiley, stands at the forefront of dermatological science, emphasizing innovative research and technological advances in skin health. With an ISSN of 0909-752X and an E-ISSN of 1600-0846, this journal serves as a vital platform for researchers and professionals to present their findings and engage in discussions surrounding skin biology, clinical practices, and therapeutic technologies. As evidenced by its respectable Q2 ranking in the dermatology category for 2023 and a Q3 status in miscellaneous medicine, the journal attracts a broad readership and contributes significantly to the field. Housed in the United Kingdom with publications spanning from 1995 to 2024, SKIN RESEARCH AND TECHNOLOGY continues to foster innovation and knowledge dissemination in skin-related research. While its Access options are not open, the impact of the journal remains prominent, appealing to academic professionals and students eager to explore emerging trends and advancements in dermatological studies.

CONTACT DERMATITIS, published by WILEY, is a leading international journal focused on the vital field of dermatology, particularly examining the diagnosis, treatment, and management of contact dermatitis and related skin conditions. With origins dating back to 1975 and a planned convergence period extending to 2024, this esteemed journal serves as a crucial resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge in dermatological practices. In the latest rankings, it has achieved a commendable Q2 classification in Dermatology and Q3 classification in Immunology and Allergy for 2023, underscoring its significance within these dynamic fields. Moreover, it holds a notable ranking of #29/142 in Medicine & Dermatology and #130/233 in Medicine & Immunology and Allergy according to Scopus metrics, placing it in the top tier of scholarly publications. While the journal operates on a subscription basis, its comprehensive reviews, original articles, and insightful research findings are invaluable for pushing the boundaries of current dermatological and immunological knowledge. By fostering a deeper understanding of the complexities of skin reactions and their implications, CONTACT DERMATITIS plays a vital role in connecting research with clinical practice, making it an essential read for anyone engaged in the field.

Indian Journal of Paediatric Dermatology (ISSN: 2319-7250; E-ISSN: 2319-7269), published by Wolters Kluwer Medknow Publications, stands as a pivotal resource in the specialized field of paediatric dermatology. As a peer-reviewed open access journal since 2013, it aims to disseminate cutting-edge research, clinical practices, and innovative developments that cater to the specific dermatological needs of children. The journal provides an essential forum for collaboration among researchers, clinicians, and students, facilitating the sharing of knowledge on a wide array of topics, including skin conditions unique to paediatric populations, treatment methodologies, and advancements in dermatological care. With a commitment to enhancing the understanding and treatment of paediatric skin diseases, this journal plays a critical role in shaping best practices and informing future research directions in a rapidly evolving field.

Dermatologica Sinica, published by Wolters Kluwer Medknow Publications, is an esteemed open-access journal in the field of dermatology that has been disseminating critical research since its inception in 2005. With an E-ISSN of 2223-330X and an ISSN of 1027-8117, this journal presents a platform for researchers, clinicians, and students to share cutting-edge findings and advancements in dermatological science. As of 2023, it proudly ranks in the Q2 category of dermatology journals and holds a notable position at rank #62 out of 142 in the Scopus Medicine - Dermatology category, placing it in the 56th percentile for impact. The journal transitioned to an open-access model in 2016, enhancing accessibility and visibility for groundbreaking studies worldwide. With a commitment to fostering innovation in the dermatological community, Dermatologica Sinica aims to advance the understanding and treatment of skin diseases while encouraging scholarly dialogue among practitioners and researchers across the globe.

The British Journal of Dermatology, published by Oxford University Press, stands as a premier platform for advancing the field of dermatological research and clinical practice since its inception in 1892. With a strong commitment to disseminating high-quality research, this esteemed journal is currently ranked in the Q1 category for both Dermatology and Miscellaneous Medicine in 2023, reflecting its influential position in the academic landscape. As the leading journal in its field, it enjoys a robust Scopus ranking of #1 out of 142 in dermatology, placing it in the 99th percentile globally. The journal covers a wide scope of subjects pertinent to dermatology, including clinical trials, treatment innovations, and epidemiological studies, making it an essential resource for researchers, healthcare professionals, and students alike. Although it is not an open-access publication, it ensures a broad reach through institutional subscriptions, fostering knowledge exchange across the global dermatological community. Based in the heart of the United Kingdom, the British Journal of Dermatology continues to play a crucial role in shaping the future of skin health and disease management.

Dermatitis, published by MARY ANN LIEBERT, INC, is a leading journal that focuses on the study of skin inflammation and allergic reactions, making significant contributions to the fields of Dermatology, Immunology, and Allergy. With an ISSN of 1710-3568 and an E-ISSN of 2162-5220, this peer-reviewed journal serves as a critical platform for researchers, healthcare professionals, and students alike, eager to share and explore groundbreaking findings and developments. Recognized for its impact and rigorous scholarly standards, Dermatitis has achieved a Q2 quartile ranking in dermatology and a Q3 ranking in immunology and allergy as of 2023, underscoring its significance in these vital medical sectors. The journal's Scopus ranking places it in the 84th percentile for dermatology and the 50th percentile for immunology and allergy, reflecting its wide acceptance and influence. With a scope spanning from 2004 to 2024, Dermatitis invites original research, reviews, and clinical updates that advance the understanding of skin disorders and therapy innovations, solidifying its role as an essential resource in enhancing skin health worldwide.

Current Dermatology Reports is a distinguished journal published by SPRINGER that focuses on the latest advancements and research in the field of dermatology. With an ISSN of 2162-4933, this journal provides a vital platform for clinicians, researchers, and students to disseminate groundbreaking findings and emerging trends pertinent to skin health. Notably recognized within the Q2 category in Dermatology for 2023, it ranks 50th out of 142 journals in the Scopus database, placing it in the 65th percentile among its peers. This accessible journal, which has been converging scholarly contributions since its establishment in 2012, plays a crucial role in bridging the gap between clinical practice and research, thereby enhancing patient care and advancing scientific understanding of skin-related issues. The editorial team is committed to the rigorous peer-review process, ensuring high-quality publications that reflect the evolving landscape of dermatology. Researchers and healthcare professionals are invited to contribute and engage with content that pushes the boundaries of knowledge in this dynamic discipline.

Przeglad Dermatologiczny is a peer-reviewed open-access journal published by TERMEDIA PUBLISHING HOUSE LTD, based in Poland. Since its establishment in 1951, this journal has been dedicated to advancing the field of dermatology by providing a platform for the dissemination of original research, reviews, and clinical case studies. With an e-ISSN of 2084-9893, it has gained recognition within the academic community, despite its current classification in the Q4 quartile of dermatological journals. The journal has been openly accessible since 2009, promoting wider dissemination of scientific knowledge, and is crucial for researchers, professionals, and students alike. While it holds a current rank of #105 out of 142 in the Scopus Dermatology category, the journal continually strives to enhance its impact through quality publications that address pressing dermatological issues. The diverse range of topics covered in the journal ensures it remains a vital resource for those looking to stay informed on the latest developments in dermatological research.

Journal of Drugs in Dermatology, an esteemed publication in the field of dermatology, serves as a vital resource for researchers, clinicians, and healthcare professionals dedicated to advancing knowledge and practices in skin-related therapies and treatments. Established in 2002 and published in the United States, this journal focuses on a wide range of topics pertinent to dermatological pharmacology and therapeutics, reflecting contemporary scientific advancements and innovative approaches to patient care. With a strong presence in Scopus rankings, situating it at rank #73 within the dermatology category, and achieving a commendable Q2 quartile classification in both dermatology and general medicine categories, the journal is committed to enhancing understanding of drug efficacy and safety in dermatological conditions. While the journal maintains a traditional access model, its impact factor underscores its significance in the research community, supporting the ongoing dialogue between academia and clinical practice. We invite professionals and students alike to explore the latest findings and contribute to the progressive discourse on dermatological treatments through this important publication.